~~<i id='11A9A78043'><strike id='11A9A78043'><tt id='11A9A78043'><pre id='11A9A78043'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：comprehensive 2025-10-08 22:28:43 Page View：34467

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Stopping antidepressants leads to symptoms for 1 in 6 patients
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Eliminate the waiting period for sterilization covered by Medicaid

AdobeIt’stimetoacknowledgewhenalawintendedtorightanegregiouswronghasbecomeharmful—andchangeit.That’s

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

UnitedHealth CEO's Medicaid comments send insurer stocks diving

UnitedHealthGroupCEOAndrewWittysaidthecompanywasbeginningtoseea“disturbance”initsMedicaidmedicalcost